Background: Coronary intervention therapy is the main treatment for uremic patients with coronary heart disease. The studies on whether dialysis reduces the efficacy of dual antiplatelet drugs are limited. The aim of this study was to examine the effect of dialysis on antiplatelet drugs in uremic patients with coronary heart disease.
Methods: This study included 26 uremic patients who had undergone percutaneous coronary intervention in China-Japan Friendship Hospital from November 2015 to May 2017. We examined their thromboelastography results before and after hemodialysis. Self-paired t-tests were employed to analyze changes in the inhibition rate of platelet aggregation.
Results: The mean inhibition rates of arachidonic acid-induced platelet aggregation before and after hemodialysis were 82.56 ± 2.79% and 86.42 ± 3.32%, respectively (t= -1.278, P= 0.213). The mean inhibition rates of adenosine diphosphate-induced platelet aggregation before and after hemodialysis were 67.87 ± 5.10% and 61.94 ± 5.90%, respectively (t = 1.425, P= 0.167). There was no significant difference in the inhibition rates of platelet aggregation before or after hemodialysis. These results also applied to patients with different sensitivity to aspirin and clopidogrel.
Conclusion: Dialysis did not affect the antiplatelet effects of aspirin and clopidogrel in uremic patients with coronary heart disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555124 | PMC |
| http://dx.doi.org/10.4103/0366-6999.211888 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Possible Role of Plant-Based Bars Consumption in CKD Geriatric Patients.
Pharmaceuticals (Basel)
December 2024
Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
: Chronic kidney disease (CKD) geriatric patients experience a premature aging process, compared with the general population of the same age and sex. The uremic milieu is capable of enhancing oxidative stress (OS) and microinflammation, leading to a pro-aging mechanism and an increased protein catabolism. Moreover, cognitive disorders are observed.
View Article and Find Full Text PDF[Uremic Leontiasis Ossea: A Challenge in End-Stage Chronic Kidney Disease. About a Case].
Rev Med Chil
May 2024
Departamento de Nefrología, Clínica Dávila, Santiago, Chile.
Article Synopsis
- Uremic leontiasis ossia (ULO) is a rare condition linked to renal osteodystrophy in patients with end-stage chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPTH), causing bone deformities that can lead to a 'leonine' facial appearance.
- The case study focuses on a 39-year-old female patient undergoing treatment, who exhibited significant symptoms and had elevated parathyroid hormone (PTH) levels, confirmed by CT scans.
- Treatment involves a multidisciplinary approach including surgery and management of SHPTH to correct anatomical issues and prevent further complications.
Leontiasis ossea in the setting of chronic kidney disease and limited dialysis access: A case report with discussion of therapeutic implications.
Radiol Case Rep
March 2025
Department of Family Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.
Article Synopsis
- Leontiasis ossea, or craniofacial fibrous dysplasia, is a rare condition that causes abnormal growth of facial bones, often linked to chronic kidney disease and high parathyroid hormone levels.
- A case of a 30-year-old male with severe facial swelling and bone changes highlights the rapid progression of symptoms after poor dialysis access and the persistence of hyperparathyroidism despite treatment efforts.
- The article also reviews the underlying causes, imaging techniques used for diagnosis, and management strategies for this complex disease.
How Uremic Toxins Alter Atorvastatin Disposition: Molecular Mechanisms of Inhibition of the Enzyme CYP3A4.
Balkan Med J
January 2025
Department of Clinical Pharmacy, China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, China.
Article Synopsis
- Uremic patients accumulate protein-bound uremic toxins (PBUTs), which alter drug metabolism by affecting the environment around liver cells and CYP450 enzymes.
- The study found that specific PBUTs like indoxyl sulfate (IS) and hippurate (HA) significantly inhibit the metabolism of atorvastatin (ATV), with IS being the most impactful, reducing ATV metabolism by over 50%.
- Results showed that the expression of the enzyme CYP3A4, critical for drug metabolism, was downregulated in the presence of uremic serum, leading to decreased ATV uptake and excretion due to effects on related signaling pathways.
Alterations in structural and functional connectivity of thalamic subregions in patients with uremic pruritus undergoing peritoneal dialysis.
Neuroscience
December 2024
Department of Medical Imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address:
Uremic pruritus (UP) significantly compromises the quality of life in patients with end-stage renal disease undergoing peritoneal dialysis. Although the precise pathophysiological mechanisms of UP remain elusive, the thalamus, which is integral to processing sensory information, is potentially implicated in its development. This study aimed to investigate alterations in the structure and resting-state functional connectivity (rsFC) of thalamic subregions in patients with UP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!